GSKGLAXF 69 Debt-to-Equity is 1.07 as of Mar. 2026, which is 41% below its 10-year median of 1.82. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.82 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, GSK ranks worse than 86.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for GSK's Debt-to-Equity or its related term are showing as below:
GLAXF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -253 Med: 1.82 Max: 140.3
Current: 1.07
During the past 13 years, the highest Debt-to-Equity Ratio of GSK was 140.30. The lowest was -253.00. And the median was 1.82.
GLAXF's Debt-to-Equity is ranked worse than 86.9% of 809
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs GLAXF: 1.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
GSK Debt-to-Equity Related Terms
GSK Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for GSK's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLAXF vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, GSK's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where GSK's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a Debt-to-Equity of 1.07 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on GSK and its competitors. This is 41% below median its historical median of 1.82. According to the industry distribution chart, GSK ranks #703 out of 809 companies in the Drug Manufacturers industry, placing it in the top 86.9%.
Is GSK's Debt-to-Equity too high?
GSK's current Debt-to-Equity of 1.07 is 41% below median its 10-year median of 1.82. The Drug Manufacturers industry median Debt-to-Equity is 0.27. GSK's value of 1.07 is 296.3% above this industry median. Based on the distribution chart, GSK ranks #703 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #703 out of 809 companies for Debt-to-Equity. This places GSK in the lower half of its industry. The industry median Debt-to-Equity is 0.27. GSK's value of 1.07 is 296.3% above this benchmark. While the company's 10-year median is 1.82 vs. the industry median of 0.27, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Debt-to-Equity of 1.07 is 296.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Debt-to-Equity is 1.07, which is 41% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.82, compared to a current price of $25.77 — trading 18.1% above its estimated fair value. The current Debt-to-Equity is 1.07, which is 41% below median its 10-year median of 1.82 and 296.3% above the Drug Manufacturers industry median of 0.27. GSK's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For GSK (GLAXF), the current Debt-to-Equity is 1.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.77 is trading 18.1% above its estimated GF Value™ of $21.82.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Debt-to-Equity: 1.07 (41% below median its 10-year median of 1.82)
GF Value™: $21.82 vs. price of $25.77 (18.1% above fair value)
Industry Position: 296.3% above the Drug Manufacturers median (#703 of 809)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
